174 related articles for article (PubMed ID: 33010988)
1. Inflammatory markers as prognostic factors in metastatic castration-resistant prostate cancer.
Donate-Moreno MJ; Lorenzo-Sánchez MV; Díaz de Mera-Sánchez Migallón I; Herraiz-Raya L; Esper-Rueda JA; Legido-Gómez O; Rico-Marco S; Salinas-Sánchez AS
Actas Urol Esp (Engl Ed); 2020 Dec; 44(10):692-700. PubMed ID: 33010988
[TBL] [Abstract][Full Text] [Related]
2. Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients.
Chong W; Zhang Z; Luo R; Gu J; Lin J; Wei Q; Li B; Myers R; Lu-Yao G; Kelly WK; Wang C; Yang H
BMC Cancer; 2021 Jun; 21(1):655. PubMed ID: 34078304
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of an inflammatory index for patients with metastatic castration-resistant prostate cancer.
Yamada Y; Sakamoto S; Rii J; Yamamoto S; Kamada S; Imamura Y; Nakamura K; Komiya A; Nakatsu H; Ichikawa T
Prostate; 2020 May; 80(7):559-569. PubMed ID: 32134137
[TBL] [Abstract][Full Text] [Related]
4. Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel.
Man YN; Chen YF
Int Urol Nephrol; 2019 Dec; 51(12):2189-2199. PubMed ID: 31456101
[TBL] [Abstract][Full Text] [Related]
5. Platelet-lymphocyte and neutrophil-lymphocyte ratios are prognostic but not predictive of response to abiraterone acetate in metastatic castration-resistant prostate cancer.
Lozano Martínez AJ; Moreno Cano R; Escobar Páramo S; Salguero Aguilar R; Gonzalez Billalabeitia E; García Fernández R; De La Fuente Muñoz I; Romero Borque A; Porras Martínez M; Lopez Soler F; Cardenas Cánovas E; Ortega Martín I
Clin Transl Oncol; 2017 Dec; 19(12):1531-1536. PubMed ID: 28718070
[TBL] [Abstract][Full Text] [Related]
6. Leukocyte and platelet counts as prognostic values of testicular germ cell tumours.
Herraiz-Raya L; Moreillo-Vicente L; Martínez-Ruiz J; Agustí-Martínez A; Fernández-Anguita PJ; Esper-Rueda JA; Salce-Marte L; Armas-Álvarez A; Díaz de Mera-Sánchez Migallón I; Martínez-Alfaro C; Giménez-Bachs JM; Donate-Moreno MJ; Salinas-Sánchez AS
Actas Urol Esp (Engl Ed); 2019; 43(6):284-292. PubMed ID: 31085041
[TBL] [Abstract][Full Text] [Related]
7. Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis.
Guan Y; Xiong H; Feng Y; Liao G; Tong T; Pang J
Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):220-231. PubMed ID: 32034294
[TBL] [Abstract][Full Text] [Related]
8. COMPLETE BLOOD COUNT DERIVED INFLAMMATORY BIOMARKERS IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES.
Nanava N; Betaneli M; Giorgobiani G; Chikovani T; Janikashvili N
Georgian Med News; 2020 May; (302):39-44. PubMed ID: 32672687
[TBL] [Abstract][Full Text] [Related]
9. Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort.
Neuberger M; Goly N; Skladny J; Milczynski V; Weiß C; Wessels F; Nitschke K; Grüne B; Haney CM; Hartung F; Herrmann J; Jarczyk J; Kowalewski KF; Waldbillig F; Kriegmair MC; Westhoff N; Worst TS; Nuhn P
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3371-3381. PubMed ID: 35939112
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu-PSMA-617.
Şahin E; Kefeli U; Zorlu Ş; Seyyar M; Ozkorkmaz Akdag M; Can Sanci P; Karakayali A; Ucuncu Kefeli A; Bakkal Temi Y; Cabuk D; Uygun K
Medicine (Baltimore); 2023 Nov; 102(47):e35843. PubMed ID: 38013293
[TBL] [Abstract][Full Text] [Related]
11. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
12. The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone.
Boegemann M; Schlack K; Thomes S; Steinestel J; Rahbar K; Semjonow A; Schrader AJ; Aringer M; Krabbe LM
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208664
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
Sonpavde G; Pond GR; Armstrong AJ; Clarke SJ; Vardy JL; Templeton AJ; Wang SL; Paolini J; Chen I; Chow-Maneval E; Lechuga M; Smith MR; Michaelson MD
Clin Genitourin Cancer; 2014 Oct; 12(5):317-24. PubMed ID: 24806399
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
15. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of pretreatment inflammatory biomarkers as independent prognostic indicators in prostate cancer.
Sun Z; Ju Y; Han F; Sun X; Wang F
J Clin Lab Anal; 2018 Mar; 32(3):. PubMed ID: 28605139
[TBL] [Abstract][Full Text] [Related]
17. The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study).
Bauckneht M; Rebuzzi SE; Signori A; Frantellizzi V; Murianni V; Lodi Rizzini E; Mascia M; Lavelli V; Donegani MI; Ponzano M; Gaudiano A; Stazza ML; Licari M; Cavallini L; Laghi V; Cindolo L; Maggi M; Sciarra A; Mammucci P; Sambuceti G; Costa RP; Spanu A; Rubini G; Monari F; De Vincentis G; Fornarini G
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1063-1074. PubMed ID: 34486070
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel.
Buttigliero C; Pisano C; Tucci M; Vignani F; Bertaglia V; Iaconis D; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
Acta Oncol; 2017 Apr; 56(4):555-562. PubMed ID: 28068151
[TBL] [Abstract][Full Text] [Related]
19. Naples Prognostic Score Is a Useful Prognostic Marker in Patients With Metastatic Colorectal Cancer.
Miyamoto Y; Hiyoshi Y; Daitoku N; Okadome K; Sakamoto Y; Yamashita K; Kuroda D; Sawayama H; Iwatsuki M; Baba Y; Yoshida N; Baba H
Dis Colon Rectum; 2019 Dec; 62(12):1485-1493. PubMed ID: 31567920
[TBL] [Abstract][Full Text] [Related]
20. The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.
Onal C; Sedef AM; Kose F; Oymak E; Guler OC; Sumbul AT; Aksoy S; Akkus Yildirim B; Besen AA; Muallaoglu S; Mertsoylu H; Ozyigit G
Future Oncol; 2019 May; 15(13):1469-1479. PubMed ID: 30977383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
